Neurotech International Ltd
Company Profile
Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUST: +61 394983132
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
18
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.60 | 88.90 | -0.99% |
| CAC 40 | 8,150.42 | 58.67 | -0.71% |
| DAX 40 | 24,795.94 | 328.23 | -1.31% |
| Dow JONES (US) | 50,687.07 | 620.72 | -1.21% |
| FTSE 100 | 10,332.30 | 41.21 | -0.40% |
| HKSE | 25,303.33 | 329.88 | -1.29% |
| NASDAQ | 26,853.98 | 239.92 | -0.89% |
| Nikkei 225 | 67,101.83 | 1,300.30 | -1.90% |
| NZX 50 Index | 13,069.43 | 45.65 | -0.35% |
| S&P 500 | 7,553.68 | 56.10 | -0.74% |
| S&P/ASX 200 | 8,652.70 | 92.90 | -1.06% |
| SSE Composite Index | 4,066.39 | 17.59 | -0.43% |